Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -14.54% is 44% above its 5-year average of -26.00%, near the high end of its 5-year range (-74.69%–10.99%).
70.04% above its 12-month average of -48.52%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -6.14%.
RETURN ON ASSETS (ROA)
-14.54%
RETURN ON ASSETS (ROA) AVG TTM
-48.52%
RETURN ON ASSETS (ROA) AVG 3Y
-33.40%
RETURN ON ASSETS (ROA) AVG 5Y
-26.00%
RETURN ON ASSETS (ROA) AVG 10Y
-26.57%
RETURN ON ASSETS (ROA) AVG 15Y
-23.79%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+70.04%
CURRENT VS 3Y AVG
+56.46%
CURRENT VS 5Y AVG
+44.07%
CURRENT VS 10Y AVG
+45.29%
CURRENT VS 15Y AVG
+38.88%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.37%
median of 791 covered companies
CURRENT VS SECTOR MEDIAN
+53.65%
vs the sector median at left
Prothena Corporation plc
Market Cap
$413.10M
Return on Assets (ROA)
-14.54%
TTM Avg
-48.52%
3Y Avg
-33.40%
5Y Avg
-26.00%
Market Cap
$412.95M
Return on Assets (ROA)
-68.75%
TTM Avg
-55.58%
3Y Avg
-51.15%
5Y Avg
-46.76%
Market Cap
$410.81M
Return on Assets (ROA)
12.09%
TTM Avg
1.03%
3Y Avg
-6.34%
5Y Avg
-7.45%
Market Cap
$407.99M
Return on Assets (ROA)
-41.33%
TTM Avg
-54.52%
3Y Avg
-54.52%
5Y Avg
-54.52%
Market Cap
$416.52M
Return on Assets (ROA)
-17.62%
TTM Avg
-32.09%
3Y Avg
-24.12%
5Y Avg
-19.05%
Market Cap
$409.37M
Return on Assets (ROA)
-23.05%
TTM Avg
-30.00%
3Y Avg
-27.77%
5Y Avg
-27.77%
Market Cap
$407.07M
Return on Assets (ROA)
-45.47%
TTM Avg
-26.84%
3Y Avg
-30.13%
5Y Avg
-31.02%
Market Cap
$408.54M
Return on Assets (ROA)
-71.16%
TTM Avg
-43.23%
3Y Avg
-31.68%
5Y Avg
-18.72%
Market Cap
$418.36M
Return on Assets (ROA)
-61.86%
TTM Avg
-66.50%
3Y Avg
-24.17%
5Y Avg
-122.74%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Prothena Corporation plc (PRTA) | $413.10M | -14.54% | -48.52% | -33.40% | -26.00% |
| Rezolute, Inc. (RZLT)vs › | $412.95M | -68.75% | -55.58% | -51.15% | -46.76% |
| Strata Critical Medical, Inc. (SRTA)vs › | $410.81M | 12.09% | 1.03% | -6.34% | -7.45% |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $407.99M | -41.33% | -54.52% | -54.52% | -54.52% |
| Myriad Genetics, Inc. (MYGN)vs › | $416.52M | -17.62% | -32.09% | -24.12% | -19.05% |
| Shoulder Innovations, Inc. (SI)vs › | $409.37M | -23.05% | -30.00% | -27.77% | -27.77% |
| Neurogene Inc. (NGNE)vs › | $407.07M | -45.47% | -26.84% | -30.13% | -31.02% |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $408.54M | -71.16% | -43.23% | -31.68% | -18.72% |
| Senseonics Holdings, Inc. (SENS)vs › | $418.36M | -61.86% | -66.50% | -24.17% | -122.74% |
| Carlsmed, Inc. (CARL)vs › | $405.61M | -30.75% | -34.79% | -68.11% | -68.11% |
ROA
-14.5%
ROE
-15.3%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -74.69% |
| 2024-12-31 | -22.36% |
| 2023-12-31 | -21.11% |
| 2022-12-31 | -15.43% |
| 2021-12-31 | 10.99% |
| 2020-12-31 | -33.38% |
| 2019-12-31 | -18.53% |
| 2018-12-31 | -31.20% |
| 2017-12-31 | -30.87% |
| 2016-12-31 | -34.81% |
| 2015-12-31 | -20.93% |
| 2014-12-31 | -2.35% |
| 2013-12-31 | -22.47% |
| 2012-12-31 | -32.03% |
| 2011-12-31 | -820.07% |
| 2010-12-31 | -378.24% |
